Research programme: antifungals - Ranbaxy

Drug Profile

Research programme: antifungals - Ranbaxy

Alternative Names: RBx 4467; RBx 7635; RBx 9050

Latest Information Update: 06 Jan 2009

Price : $50

At a glance

  • Originator Ranbaxy Laboratories
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo Company
  • 03 Feb 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the Mycoses pharmacodynamics and antimicrobial activity sections
  • 12 Nov 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top